AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7936364 — intervention group
Group type: EXPERIMENTAL
Intervention: NCC-LU-246
Number of subjects: 40
Study 7936364 — intervention group
Group type: EXPERIMENTAL
Intervention: NCC-LU-243
Number of subjects: 40
Study 7936364 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocytochemistry with anti-NCAM MAbs
Number of subjects: 40
Study 3284336 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ethanolamine oleate
Number of subjects: 47
Study 3284336 — intervention group
Group type: COMPARATOR
Intervention: absolute alcohol
Number of subjects: 47
Study 11100226 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II glass ionomer cement
Number of subjects: 50
Study 11100226 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfilled composite resin
Number of subjects: 50
Study 4812364 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 15 mg/kg per dose for 5 doses
Number of subjects: 95
Study 4812364 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous catheterization
Number of subjects: 95
Study 4812364 — intervention group
Group type: COMPARATOR
Intervention: Control group (open arteriotomy or no aspirin)
Number of subjects: 95
Study 31491416 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative image set
Number of subjects: 210
Study 31491416 — intervention group
Group type: COMPARATOR
Intervention: Preoperative image set
Number of subjects: 210
Study 31512025 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat acclimation (HA) training at 38.0 °C for 10 days
Number of subjects: 22
Study 31512025 — intervention group
Group type: COMPARATOR
Intervention: Control (Con) training at 20 °C for 10 days
Number of subjects: 22
Study 28027198 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetics
Number of subjects: 40
Study 28027198 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (1:1 mixture of 1% lidocaine and TA)
Number of subjects: 40
Study 28027198 — intervention group
Group type: COMPARATOR
Intervention: Control (no anesthetic)
Number of subjects: 40
Study 28027198 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (1% lidocaine)
Number of subjects: 40
Study 26364532 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program applying Dongsasub training
Number of subjects: 38
Study 26364532 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 23884826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine bolus 5 mg plus ephedrine infusion
Number of subjects: 110
Study 23884826 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine bolus 5 mg plus normal saline infusion
Number of subjects: 110
Study 21339543 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Number of subjects: 60
Study 21339543 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breathing exercises)
Number of subjects: 60
Study 19666643 — intervention group
Group type: EXPERIMENTAL
Intervention: candesartan 8 mg/day
Number of subjects: 171
Study 19666643 — intervention group
Group type: EXPERIMENTAL
Intervention: candesartan 16 mg/day
Number of subjects: 171
Study 19666643 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 171
Study 17850984 — intervention group
Group type: EXPERIMENTAL
Intervention: 4x25 microg GHRH intravenously
Number of subjects: 2
Study 17850984 — intervention group
Group type: EXPERIMENTAL
Intervention: 4x50 microg GHRH intravenously
Number of subjects: 2
Study 17850984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 15848527 — intervention group
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (MMF), prednisone, daclizumab, and reduced CsA dose (5 mg per kg per day for 7 months followed by complete withdrawal)
Number of subjects: 42
Study 15848527 — intervention group
Group type: COMPARATOR
Intervention: normal CsA dose (10 mg per kg per day adjusted according to C2 levels), MMF, prednisone, and no daclizumab
Number of subjects: 42
Study 11548984 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (Rebif) 44 mcg subcutaneously three times per week
Number of subjects: 560
Study 11548984 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (Rebif) 22 mcg subcutaneously three times per week
Number of subjects: 560
Study 11548984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study 9505784 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg (group D)
Number of subjects: 60
Study 9505784 — intervention group
Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 60
Study 8042587 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori infection
Number of subjects: 31
Study 8042587 — intervention group
Group type: COMPARATOR
Intervention: Normal histologic characteristics (Control)
Number of subjects: 31
Study 8042587 — intervention group
Group type: COMPARATOR
Intervention: H pylori-negative gastritis (Control)
Number of subjects: 31
Study 8042587 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori infection with duodenal ulcers
Number of subjects: 31
Study 8042587 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori infection without mucosal ulceration
Number of subjects: 31
Study 3275748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) to 20 Gy using high‐energy electrons followed by low‐dose (35 to 40 Gy) postoperative external beam irradiation
Number of subjects: 35
Study 3275748 — intervention group
Group type: COMPARATOR
Intervention: High‐dose (50 to 55 Gy) postoperative external beam irradiation
Number of subjects: 35
Study 28222575 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected pacing strategy (SSP)
Number of subjects: 15
Study 28222575 — intervention group
Group type: COMPARATOR
Intervention: Negative pacing strategy (NPS)
Number of subjects: 15
Study 28222575 — intervention group
Group type: COMPARATOR
Intervention: Even pacing strategy (EPS)
Number of subjects: 15
Study 27491605 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1480
Study 27491605 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1480
Study 25331468 — intervention group
Group type: EXPERIMENTAL
Intervention: Allitridi capsules (120 mg/day)
Number of subjects: 80
Study 25331468 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 80
Study 22483593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subacromial injection with triamcinolone 40mg
Number of subjects: 58
Study 22483593 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (placebo)
Number of subjects: 58
Study 20522795 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 23
Study 20522795 — intervention group
Group type: COMPARATOR
Intervention: valsartan (160 mg)
Number of subjects: 23
Study 18042102 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyflex stent (N=47)
Number of subjects: 101
Study 18042102 — intervention group
Group type: COMPARATOR
Intervention: Ultraflex stent (N=54)
Number of subjects: 101
Study 16274096 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-site temporary triggered pacing in the AAT mode at a lower rate of 40 beats/min for 4 days
Number of subjects: 70
Study 16274096 — intervention group
Group type: COMPARATOR
Intervention: No pacing (control group)
Number of subjects: 70
Study 16274096 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-site temporary triggered pacing
Number of subjects: 70
Study 12017396 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide-beta-cyclodextrin (400 mg BID, orally = 100 mg nimesulide BID)
Number of subjects: 0
Study 12017396 — intervention group
Group type: COMPARATOR
Intervention: naproxen (500 mg BID)
Number of subjects: 0
Study 12017396 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide-beta-cyclodextrin
Number of subjects: 0
Study 12017396 — intervention group
Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 0
Study 10492407 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine and 10 mg preservative-free pethidine (group LP)
Number of subjects: 60
Study 10492407 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine, 10 mg preservative-free pethidine and 20 mg tenoxicam (group LPT)
Number of subjects: 60
Study 8934067 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniplant contraceptive implant
Number of subjects: 819
Study 1725913 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 1725913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6858516 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30413181 — intervention group
Group type: EXPERIMENTAL
Intervention: Methenamine hippurate
Number of subjects: 0
Study 30413181 — intervention group
Group type: COMPARATOR
Intervention: Daily low-dose antibiotics
Number of subjects: 0
Study 30413181 — intervention group
Group type: EXPERIMENTAL
Intervention: Health economic outcomes
Number of subjects: 0
Study 30413181 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative study
Number of subjects: 0
Study 27435205 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate carotid endarterectomy
Number of subjects: 2333
Study 27435205 — intervention group
Group type: COMPARATOR
Intervention: Delayed carotid endarterectomy
Number of subjects: 2333
Study 27435205 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior cerebral infarction
Number of subjects: 2333
Study 24852946 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol candy (7.5 g daily intake)
Number of subjects: 485
Study 24852946 — intervention group
Group type: COMPARATOR
Intervention: Xylitol candy (7.5 g daily intake)
Number of subjects: 485
Study 24852946 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol candy (7.5 g daily intake)
Number of subjects: 485
Study 22381809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus monotherapy
Number of subjects: 58
Study 22381809 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus and prednisone dual therapy
Number of subjects: 58
Study 21383479 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX‐free ASF mouthrinse
Number of subjects: 42
Study 21383479 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX mouthrinse
Number of subjects: 42
Study 21383479 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 42
Study 17609246 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF treatment
Number of subjects: 50
Study 17609246 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched fertile women)
Number of subjects: 50
Study 16306249 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk assessment program including apolipoprotein E genotype disclosure
Number of subjects: 162
Study 16306249 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk assessment program
Number of subjects: 162
Study 12075253 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 264
Study 12075253 — intervention group
Group type: EXPERIMENTAL
Intervention: No symptomatic recurrences of AF
Number of subjects: 264
Study 12075253 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 264
Study 12075253 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 264
Study 12075253 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone, Sotalol, Propafenone
Number of subjects: 264
Study 10442959 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered group (22 patients)
Number of subjects: 44
Study 10442959 — intervention group
Group type: COMPARATOR
Intervention: Control group (22 patients)
Number of subjects: 44
Study 7790689 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake
Number of subjects: 136
Study 7790689 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein intake
Number of subjects: 136
Study 7790689 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BUN and less malnutrition at entry
Number of subjects: 136
Study 7790689 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood urea nitrogen (BUN) and high serum creatinine
Number of subjects: 136
Study 2189328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Number of subjects: 50
Study 2189328 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 50
Study 110212 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily (A‐50)
Number of subjects: 0
Study 110212 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily (A‐100)
Number of subjects: 0
Study 110212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30851050 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with anti-adhesive zinc-substituted carbonated hydroxyapatite (HA)
Number of subjects: 41
Study 30851050 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste with antimicrobial and anti-adhesive amine fluoride/stannous fluoride (AmF/SnF2)
Number of subjects: 41
Study 30851050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both toothpaste formulations
Number of subjects: 41
Study 29023536 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training and nutritional support (PTN)
Number of subjects: 58
Study 29023536 — intervention group
Group type: COMPARATOR
Intervention: Social support (SoSu)
Number of subjects: 58
Study 26285327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous laser irradiation of the blood in addition to traditional medicamental treatment (n = 102)
Number of subjects: 132
Study 26285327 — intervention group
Group type: COMPARATOR
Intervention: Traditional medicamental treatment alone (Control group, n = 30)
Number of subjects: 132
Study 23579324 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 41
Study 23579324 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study 21034232 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope with chest compressions
Number of subjects: 20
Study 21034232 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope without chest compressions
Number of subjects: 20
Study 21034232 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope Ranger with chest compressions
Number of subjects: 20
Study 21034232 — intervention group
Group type: COMPARATOR
Intervention: GlideScope Ranger without chest compressions
Number of subjects: 20
Study 21034232 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope with chest compressions
Number of subjects: 20
Study 21034232 — intervention group
Group type: COMPARATOR
Intervention: Airway Scope without chest compressions
Number of subjects: 20
Study 19179870 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Membrane Oxygenation (ECMO) for Severe Adult Respiratory Failure
Number of subjects: 0
Study 19179870 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional lung assist (pumpless arteriovenous extracorporeal technique)
Number of subjects: 0
Study 19179870 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfiber, microporous polymethylpentene membrane lungs
Number of subjects: 0
Study 17355745 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg
Number of subjects: 984
Study 17355745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study 15100337 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline implementation intervention including a tutorial for intake clinicians, group and individual performance feedback, use of a modified vital signs stamp, offer of free nicotine replacement therapy, and proactive telephone counseling.
Number of subjects: 2163
Study 15100337 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only general information about the AHRQ Guideline.
Number of subjects: 2163
Study 11465656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 12
Study 9779342 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF prophylaxis
Number of subjects: 0
Study 9779342 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 0
Study 9364699 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosome-formulated influenza vaccine
Number of subjects: 100
Study 9364699 — intervention group
Group type: COMPARATOR
Intervention: Subunit influenza vaccine
Number of subjects: 100
Study 2388129 — intervention group
Group type: EXPERIMENTAL
Intervention: VK1 (20 mg orally)
Number of subjects: 33
Study 2388129 — intervention group
Group type: EXPERIMENTAL
Intervention: VK2 (20 mg orally)
Number of subjects: 33
Study 2388129 — intervention group
Group type: EXPERIMENTAL
Intervention: VK1 and VK2 (20 mg orally)
Number of subjects: 33
Study 2388129 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study 6790990 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated prothrombin-complex concentrate (FEIBA)
Number of subjects: 15
Study 6790990 — intervention group
Group type: COMPARATOR
Intervention: Control preparation (nonactivated prothrombin-complex concentrate)
Number of subjects: 15
Study 31116187 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 5 mm dental implants with a nanostructured calcium‐incorporated titanium surface
Number of subjects: 80
Study 31116187 — intervention group
Group type: COMPARATOR
Intervention: 10-mm or longer implants in augmented bone
Number of subjects: 80
Study 31116187 — intervention group
Group type: COMPARATOR
Intervention: Short implants in mandibles
Number of subjects: 80
Study 31116187 — intervention group
Group type: COMPARATOR
Intervention: Short implants in maxillae
Number of subjects: 80
Study 28597177 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Foundations program (intervention)
Number of subjects: 34
Study 28597177 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 26077040 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal packing
Number of subjects: 74
Study 26077040 — intervention group
Group type: COMPARATOR
Intervention: Unpacked side (control)
Number of subjects: 74
Study 24964105 — intervention group
Group type: EXPERIMENTAL
Intervention: GAL/NIM
Number of subjects: 21
Study 24964105 — intervention group
Group type: COMPARATOR
Intervention: GAL/PLA
Number of subjects: 21
Study 22198635 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1-mg reproterol and 2-mg disodium cromoglycate (DSCG)
Number of subjects: 11
Study 22198635 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting β-agonist reproterol alone
Number of subjects: 11
Study 22198635 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) alone
Number of subjects: 11
Study 22198635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 18449549 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of misoprostol vaginally (self administered) 4‐6 h prior to hysteroscopy
Number of subjects: 100
Study 18449549 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cervical priming)
Number of subjects: 100
Study 17697036 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g paracetamol
Number of subjects: 18
Study 17697036 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g paracetamol plus 30 mg dextromethorphan
Number of subjects: 18
Study 17697036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15370724 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tropisetron daily intravenous bolus injection for 5 days
Number of subjects: 21
Study 15370724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11407105 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study 11407105 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone antagonists
Number of subjects: 0
Study 9362821 — intervention group
Group type: EXPERIMENTAL
Intervention: Competency‐based, written self‐learning module
Number of subjects: 67
Study 9362821 — intervention group
Group type: COMPARATOR
Intervention: Competency‐based, didactic lecture module
Number of subjects: 67
Study 1482431 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional lidocaine infiltration (1% lidocaine, 40 mL)
Number of subjects: 37
Study 1482431 — intervention group
Group type: COMPARATOR
Intervention: Postincisional lidocaine infiltration (1% lidocaine, 40 mL)
Number of subjects: 37
Study 2861315 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 to 1.2 mg intravenously)
Number of subjects: 23
Study 2861315 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle for injection)
Number of subjects: 23
Study 31404499 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted lung denervation (TLD)
Number of subjects: 82
Study 31404499 — intervention group
Group type: COMPARATOR
Intervention: Sham bronchoscopy
Number of subjects: 82
Study 30404626 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (SRC inhibitor)
Number of subjects: 0
Study 27575492 — intervention group
Group type: EXPERIMENTAL
Intervention: Video and simulator
Number of subjects: 133
Study 27575492 — intervention group
Group type: EXPERIMENTAL
Intervention: Video only
Number of subjects: 133
Study 27575492 — intervention group
Group type: COMPARATOR
Intervention: Self-study only
Number of subjects: 133
Study 24811331 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (2 × 250 mg/d)
Number of subjects: 18
Study 24811331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 22380745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 24
Study 22380745 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Ventilation (SV)
Number of subjects: 24
Study 20095796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus paclitaxel (L + P)
Number of subjects: 579
Study 20095796 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus placebo (P + pla)
Number of subjects: 579
Study 18094551 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinPrep test with voided urine (V)
Number of subjects: 30
Study 18094551 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinPrep test with drained urine (D)
Number of subjects: 30
Study 18094551 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinPrep test with irrigated urine (I)
Number of subjects: 30
Study 18094551 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE test with voided urine (V)
Number of subjects: 30